** Shares of Imugene IMU.AX rise as much as 6.2% to A$0.345, the highest since November 6
** The biotechnology company entered a strategic collaboration with JW Therapeutics 2126.HK to evaluate a novel combination therapy to treat refractory solid tumours
** Stock up for the third straight session
** Stock currently up 3.1%, bringing YTD losses to 71.2%
(Reporting by Adwitiya Srivastava in Bengaluru)
((Adwitiya.Srivastava@thomsonreuters.com))